Saloni Goyal

Saloni Goyal

Auto-generated profile, based on publicly available information

Saloni Goyal

School ofPharmaceutical Sciences, Jaipur National University, 302015, Rajasthan, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Biological Sciences
Verified
Journal Article
Open access
SGSaloni Goyal
Saloni Goyal
VCVarunesh Chaturvedi
Varunesh Chaturvedi
GDGarima Dhingra
Garima Dhingra
STSonia Tanwar
Sonia Tanwar
KSKapil Sharma
Kapil Sharma
SSSandeep Singh
Sandeep Singh
Ajwain, dried mature seed like fruits are well known by names such as thymol seeds, caraway, carom, ajowan, or bishop's weed, belongs to the Apiaceae family. Carum copticum is the Latin name for this spice. Trachyspermum ammi (L.) Sprague ex Turrill is scientific name. This spice is indigenous to Egypt, although it is also cultivate in India, Iran, Pakistan, Iraq, Afganistan, other nations in South and West Asia as well as Europe. Gujarat and Rajasthan are Indian states noted for their ajwain cultivation. It is known as Zenyan or Nankhah in medical and pharmaceutical manuscript of medieval Persia. As Traditional Persian Medicine, Ajwain was well known from thousands of years in unani as well as ayurveda. It is used as a spice world-widely. This plant contains a variety of bioactive compunds of pharmacological importance, involving carbohydrates, fat, fibre, glycosides, protein, phenolic compounds, volatile oil (thymol, γ-terpinene, para-cymene, and α-and β-pinene), saponins and mineral content are found in this plant. The ajwain extract is known as "Admoda Arka" in Ayurveda. Ethnopharmacological values added by Vaidya gurus for coughs, colds, pain, headaches, heartburn, asthma, diarrhoea, painful menstruation, cholera, stomach discomfort, and smooth respiratory and kidney function. It has been used in modern medicine due to clinical findings of its pharmacological activities involving Bronchodilator, Cardiac Stimulant, Carminative, Digestive Stimulant, Diuretic, Galactagogue, Hypo-glycemic, Antioxidant, Antifungal, Anthelmintic, Anti-arthritic, Anti-inflammatory, Antiflatulent, Analgesic, Antimicrobial, Antihypertensive, Antifilarial. In this paper we primarily focused on Detailed phytochemistry along with Pharmcognostical and Nutritional values, also traditional and modern pharmacological role along with its safety measurement.

1 November 2022 in INDIAN DRUGS
Verified
Journal Article
Closed access
Mohammad MukimMohammad Mukim
Mohammad Mukim
MCMohit Chaturvedi
Mohit Chaturvedi
RPRakesh P. Patel
Rakesh P. Patel
SRSupriya Roy
Supriya Roy
PSPratishtha Sharma
Pratishtha Sharma
MPMohsina F. Patewkar
Mohsina F. Patewkar
Crohn’s disease (CD) is a kind of inflammatory bowel disease (IBD) characterized by the chronic transmural inflammatory state of gastrointestinal tract that typically affects ileum, colon, and perineum. Although the precise etiology is unknown, the major risk aspects concerned with CD consist of several environmental factors, altered microbiota, unhealthy low fiber- high carbohydrate diet, and certain medicines like non-steroidal anti-inflammatory drugs. The disease has wide distribution and inflammation may affect the different areas of the alimentary tract in diverse people. In about 80 % of patients, only small bowel involvement is typically present, affecting distal ileum resulting in ileitis. In about 50 % patients, both ileum and colon are affected resulting in ileocolitis and in approximately 20 % patients, disease is limited to colonic portion. Perianal disease affects almost one-third of patients. As per the various genetic researches in the CD patients, various genetic mutations affect the body’s immunological system that results in severe inflammatory state. The two major gene mutations which result in the pathological state of CD are autophagy-related 16-like 1 (ATG16L1) and nucleotidebinding oligomerization domain-containing protein 2 (NOD2/ Card15). The main techniques used for diagnosis of CD include the combination of pathological findings, endoscopic and radiographic findings demonstrating the disease features. The utmost preferred radiologic study for assessing the small bowel CD is abdominal computerized tomography (CT). The goal of current treatment strategies is to address symptomatic relief. Sequence of treatment includes induction therapy, followed by maintenance of remission. The currently used drugs that effectively can cause induction as well as maintain remission include 5-aminosalicylic acid, Tumor Necrosis Factor (TNF) inhibitors, immunomodulators and steroids. Treatment and management should be integrated with lifestyle and dietary amendments to prevent therapeutic failure and consideration of surgical intervention.

6 April 2026 in Drug Delivery Letters
Verified
Journal Article
Closed access
PDF file
Binita GhoshBinita Ghosh
Binita Ghosh
PSPratiksha Sharma
Pratiksha Sharma
SGSaloni Goyal
Saloni Goyal
VCVarunesh Chaturvedi
Varunesh Chaturvedi
KRKm Reena
Km Reena
RPRahul Pal
Rahul Pal
Introduction: Polycystic Ovary Syndrome (PCOS) presents itself as a hormonal and metabolic disorder that affects women during their reproductive years through three primary symptoms. The existing treatments encounter two main obstacles, which include their limited bioavailability and their tendency to produce adverse effects throughout the body. The application of nanotechnology to drug delivery via nanocarriers and nanoformulations offers a solution to existing challenges in the field. Methods: The research team conducted a complete literature review, which examined scientific databases from 1 May 2020 until 1 May 2025. The research team used specific keywords, along with Boolean operators (AND, OR, NOT), to locate relevant peer-reviewed articles, clinical studies, and patents focused on nanocarrier-based nanoformulations for PCOS. Results: The study results demonstrate that nanoformulations that use nanocarrier technology improve PCOS treatment through better drug solubility and bioavailability and precise medication delivery. The combination of multiple medications into one formulation leads to better treatment results while decreasing adverse reactions. The rise in patent applications demonstrates that personalized nanomedicine and hybrid delivery systems are becoming increasingly innovative as they develop. Discussion: A Nanocarrier-based PCOS treatment system provides two advantages through its ability to increase drug solubility and bioavailability while delivering targeted therapies that produce fewer adverse events. Hormonal and metabolic imbalances in patients are effectively treated by multidrug nanoformulations, which achieve better outcomes through their simultaneous multiple actions. The patent system shows that personalized medicine and hybrid nanomedicine approaches have become increasingly innovative. The results from preclinical studies show potential benefits, yet there remain obstacles, including difficulties in scaling operations, determining product safety, and proving linkages between two different fields Conclusion: The development of advanced nanocarriers represents a new medical treatment approach that enables precise medication delivery and better treatment results for patients with PCOS. The increasing volume of clinical research, together with the growing number of patents, indicates high commercial potential, yet additional research on safety and practical applications is required.